Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467 (A.K., R.P., E.M., L.B.H.); and Department of Diagnostic Radiology, University of Maryland, Baltimore, Md (C.S.W.).
Radiol Imaging Cancer. 2020 Mar 27;2(2):e190021. doi: 10.1148/rycan.2020190021. eCollection 2020 Mar.
To compare the performance of the Vancouver risk calculator (VRC) with the American College of Radiology's Lung CT Screening Reporting and Data System (Lung-RADS) for a lung cancer screening cohort in an urban, diverse clinical setting.
This study included a total of 486 patients with lung nodules (63 years ± 5.2 [standard deviation], 261 female patients), 448 of whom had lung nodules that were subsequently classified as benign and 38 of whom had those that were classified as malignant. The mean follow-up time was 40.0 months ± 14. Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act-compliant retrospective study, and a waiver of informed consent was received. All patients undergoing lung cancer screening who underwent an initial baseline screening CT between December 2012 and June 2016 that demonstrated a nodule and had at least 1 year of follow-up comprised the study population. Each examination was assigned a Lung-RADS score between 2 and 4B, with 4A and 4B considered as showing positive results. The VRC calculates the risk of cancer at different thresholds using nine variables related to patient and imaging characteristics. Analysis was performed per patient based on the largest nodule. Lung-RADS and VRC using the 5% threshold were compared to assess diagnostic performance in determining the risk of developing lung cancer in a patient with a nodule found at screening CT. The McNemar test was used to compare differences in performance between Lung-RADS and VRC.
Lung-RADS resulted in nine false-positive and 16 false-negative findings, whereas VRC with a 5% threshold resulted in 29 false-positive and 10 false-negative findings. Overall sensitivity and specificity for Lung-RADS was 58.0% and 98.0%, and for VRC with a 5% threshold was 73.7% and 93.5%, respectively ( = .313, < .001, respectively).
The VRC performs well in an urban, diverse lung cancer screening program. Further studies may be directed at determining whether its use in conjunction with Lung-RADS leads to improved lung cancer detection. CT, Lung, Thorax© RSNA, 2020.
比较温哥华风险计算器(VRC)与美国放射学院肺部 CT 筛查报告和数据系统(Lung-RADS)在城市多民族临床环境下肺癌筛查队列中的表现。
本研究共纳入 486 例肺结节患者(63 岁±5.2[标准差],261 例女性),其中 448 例肺结节为良性,38 例为恶性。平均随访时间为 40.0 个月±14.0。该符合《健康保险流通与责任法案》的回顾性研究获得机构审查委员会批准,并获得了知情同意豁免。所有接受肺癌筛查并在 2012 年 12 月至 2016 年 6 月间接受初始基线筛查 CT 检查、显示有结节且随访时间至少 1 年的患者均纳入研究人群。对所有患者,基于最大结节进行分析,将每个检查结果分配一个 2 至 4B 级的 Lung-RADS 评分,其中 4A 和 4B 级为阳性结果。VRC 使用与患者和影像学特征相关的 9 个变量计算不同阈值下的癌症风险。基于最大结节,每位患者进行分析。采用 Lung-RADS 和 VRC(5%阈值)评估在筛查 CT 检查发现结节的患者中判断发生肺癌风险的诊断性能。采用 McNemar 检验比较 Lung-RADS 和 VRC 的性能差异。
Lung-RADS 导致 9 例假阳性和 16 例假阴性结果,而 VRC(5%阈值)导致 29 例假阳性和 10 例假阴性结果。Lung-RADS 的总体敏感性和特异性分别为 58.0%和 98.0%,VRC(5%阈值)的分别为 73.7%和 93.5%( =.313,<.001)。
VRC 在城市多民族肺癌筛查项目中表现良好。进一步的研究可能会致力于确定其与 Lung-RADS 联合使用是否会提高肺癌检出率。
CT,肺,胸部© RSNA,2020。